Edwards Lifesciences Corp (EW) has experienced a
367% gain in share price due to solid performance. EW's robust earnings growth and
positive stock performance have led to Citigroup upgrading the stock and Wells Fargo acquiring nearly 20,000 shares. The company's strong quarterly performance has garnered investor interest, with strong buying by institutions such as Dimensional Fund Advisors and First Trust Bank. The
Q4 2023 financial results were favorable and the company plans to host the earnings conference call on April 24, 2014. Despite some underperformance compared to competitors on certain days, the overall trend has been positive. A planned
spin-off of the critical care unit is anticipated in 2024 and there are strong institutional backing with ownership at 83-87%.
Strong TAVR sales amidst macroeconomic issues further reinforce confidence. Amidst the good news, Edwards Lifesciences CFO, Scott B. Ullem sold 5625 shares causing a minor dip in the stock price. Despite some setbacks, analysts suggest retaining the stock for the present. EW's Q1 earnings beat estimates and the stock was raised to a buy at Citigroup. Looking forward, the company provided a positive growth strategy and outlook.
Edwards Lifesciences Corp EW News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Sun, 26 May 2024 19:11:41 GMT -
Rating 7
- Innovation 3
- Information 5
- Rumor -3
